Autor: |
Cowan KJ; Merck KGaA, Research & Development, Drug Metabolism & Pharmacokinetics New Biological Entities, 64293Darmstadt, Germany., Kunz U; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, 88400Biberach an der Riss, Germany., Blattmann P; Idorsia Pharmaceuticals Ltd, Translational Sciences, 4123Allschwil, Switzerland., Gulati P; F. Hoffmann La Roche Ltd Bioanalysis & Biomarkers Chapter, Pharmaceutical Sciences, 4070Basel, Switzerland., Hughes R; Resolian Bioanalytics, Newmarket Road, Fordham, CB7 5WW, United Kingdom., Andersen L; Novo Nordisk A/S, Clinical LCMS Bioanalysis, DK-2760, Maaløv, Denmark., Goodman J; Bioanalytical Services, Celerion, Lincoln, NE 68502, USA., Lambert F; Charles River Laboratories, Immunology, Bioanalysis & Biomarkers, EH33 2NE, Edinburgh, United Kingdom., Lawrence J; Invox Pharma, Translational Sciences, CB21 6AD, Cambridge, United Kingdom., Thwaites D; LabCorp Drug Development, LabCorp Drug Development, Immunology & Immunotoxicology, HG3 1PY, Harrogate, United Kingdom., Golob M; Nuvisan GmbH, Bioanalysis, 89231, Neu-Ulm, Germany., Nelson R; BioAgilytix Laboratories, 22339Hamburg, Germany., Timmerman P; European Bioanalysis Forum vzw (EBF), Havenlaan 86c b204, 1000Brussels, Belgium. |